Clinical Trials in Maryland

Showing 10801-10820 of 19,983 trials

Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)

NCT02445963

This study is an open-label, dose-escalating Phase 1 investigation of S. flexneri 2a InvaplexAR vaccine. A total of up to 40 subjects will receive one of four S. flexneri 2a InvaplexAR vaccine doses. The vaccine will be administered intranasally (without adjuvant).

ShigellosisBacillary Dysentery

U.S. Army Medical Research and Development Command38 participantsStarted Oct 2015

Silver Spring, Maryland, United States

COMPLETEDPhase 113 miles

Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea

NCT01644565

The purpose of the study is to determine if immunization with a chimeric E. coli protein, dsc14CfaE-sCT2/LTB5, is safe and immunogenic when administered by vaccination under the skin.

Escherichia Coli Infection

U.S. Army Medical Research and Development Command57 participantsStarted Aug 2012

Silver Spring, Maryland, United States

COMPLETEDPhase 217 miles

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

NCT03072160

Background: Medullary thyroid cancer (MTC) is a tumor of the thyroid gland. Surgery is the only current treatment to cure it. The drug pembrolizumab (MK-3475) is a new type of cancer therapy. It works by allowing the immune system to detect and kill tumor cells. Objective: To test how pembrolizumab affects people with MTC and if it can offer them clinical benefit. Eligibility: People ages 18 and older with MTC Patients who have recurrent or metastatic MTC, for whom surgery is not a curative option Patients with some imaging evidence of MTC Patients with minimal symptoms related to MTC Design: Participants will be screened with: * Medical history * Physical exam * Blood, urine, and heart tests * Computed tomography (CT) scan or magnetic resonance imaging (MRI): They lie in a machine that takes pictures of the body. * Bone scan Participants will be put in a group based on their treatment history: * Group 1 if they have had an immune stimulating cancer vaccine * Group 2 if they have had no vaccine Participants will receive the study drug as a 30-minute intravenous (IV) infusion every 3 weeks. Treatment will continue for up to 2 years as long as they tolerate it and their disease does not get worse. Participants will have physical exams and blood tests on the day of each infusion. They will have CT and bone scans every 3 months. Participants may save biopsies before treatment and after starting treatment. Participants will have a final visit 3-4 weeks after stopping treatment. This will include a physical exam and blood and heart tests. After this study, participants can join a long-term follow-up study.

Medullary Thyroid Cancer (MTC)

National Cancer Institute (NCI)17 participantsStarted Jun 2017

Bethesda, Maryland, United States

Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)

Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Find Trials by Condition in Maryland

Examining the Knowledge, Attitudes, and Beliefs of Sickle Cell Disease Patients, Parents of Patients With Sickle Cell Disease, and Providers Towards the Integration of CRISPR in Clinical Care

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

Randomized Trial to Assess PO Versus IV Antibiotics

Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma

Pharmacogenetics for Pain Management in Joint Replacement Patients

Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients

Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk

The Altis® Single Incision Sling System for Female Stress Urinary Incontinence Study

Study to Evaluate Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery

Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections

Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures

Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.